No studies were published about the CB expression as a risk factor of the preterm delivery in humans. This information could be used in clinical practice. Further studies should be performed to assess the expression of CB receptors during pregnancy. Knowledge about perinatal receptor expression could lead to improved PTB prediction. This tool could improve neonatal outcomes connected with prematurity. Amniocentesis or chorionic villus sampling could be used to examine intrauterine CB level. Moreover, liquid-based cytology could be used as a noninvasive perinatal method of measuring the expression level of CB in decidual cells during pregnancy. However, further researches seem necessary to verify this thesis.